According to researchers at the Sanford Burnham Prebys Medical Discovery Institute and the University of Michigan, researchers reported new details on June 1, 2026, in the Proceedings of the National Academy of Sciences regarding how insulin-producing beta cells coordinate protein folding and manage the cellular stress that leads to type 2 diabetes. As prediabetes advances toward diabetes, proteins inside pancreatic beta cells begin to misfold, creating accumulating stress that damages the cells responsible for producing insulin.
Why Insulin-Producing Beta Cells Become Overwhelmed
Beta cells in the pancreas monitor blood sugar levels and respond to rising glucose by producing additional insulin to restore normal ranges. As diabetes progresses, however, these cells increasingly struggle to meet the body’s demand. Previous research links this decline to the misfolding of proinsulin, the precursor protein used to make insulin. Improperly folded proinsulin accumulates during diabetes and places severe stress on pancreatic beta cells, though scientists previously lacked certainty regarding which additional partner proteins help control this process and how they work together.
“We knew that the system for preventing proinsulin misfolding depended on a chaperone protein called binding immunoglobulin protein and a number of cochaperones,” said Randal J. Kaufman, PhD, a professor in the Center for Metabolic and Liver Diseases at Sanford Burnham Prebys and senior and corresponding author of the study. “Our goal was to examine how these partner proteins coordinate proinsulin folding and remove any misfolded mistakes, as these steps are essential for the health of insulin-producing cells.”
Did You Know? Pancreatic beta cells rely heavily on specialized molecular machinery, including chaperone proteins like BiP, to manage the immense folding demands required to process proinsulin into usable insulin.
Tracking Binding Immunoglobulin Protein and p58IPK Inside Beta Cells
To study the interactions of binding immunoglobulin protein (BiP), researchers genetically modified mice so that BiP in their beta cells carried an additional amino acid chain called a peptide. According to the study, this added marker consisted of three copies of an eight-amino-acid sequence known as a 3xFLAG-tag, which acted as a molecular beacon to allow scientists to detect and isolate BiP easily during experiments.
The results highlighted an especially important role for p58IPK, one of BiP’s cochaperone proteins. When researchers genetically removed p58IPK from two different cell lines, misfolded proinsulin accumulated at higher levels. Tests in mice engineered not to produce p58IPK showed similar evidence, as their beta cells made smaller amounts of both proinsulin and insulin.
How BiP and p58IPK Work Together
The research team restored p58IPK in one of the modified cell lines, which improved the cells’ ability to fold and transport proinsulin while reducing the accumulation of improperly folded copies. However, p58IPK could not replace BiP’s central role; those improvements failed to occur unless BiP was also present.
Investigators also tested whether increasing BiP could compensate for the absence of p58IPK. When cells produced extra BiP but lacked p58IPK, they showed only modest gains in proinsulin folding and its movement out of the cell, whereas improvements were substantially greater when both proteins were present at normal levels.
“Like a single tennis player trying to play a doubles match, we found that BiP cannot just go it alone in maintaining the proper folding of proinsulin,” said Insook Jang, PhD, a staff scientist in the Kaufman lab and lead author of the manuscript.
Pro Tip: Understanding the molecular partnership between BiP and p58IPK offers researchers a clearer pathway toward targeting specific protein-folding mechanisms rather than relying solely on treatments that prompt the pancreas to release more insulin.
Potential New Diabetes Treatment Strategies
Most existing diabetes medications do not directly correct the protein-folding problems that contribute to beta cell failure. Instead, standard therapies primarily control the disease by helping tissues absorb more glucose or prompting the pancreas to release more insulin, leaving no current therapies specifically designed to improve proinsulin folding to preserve beta cell health.
“If we can learn how to influence the coordinated activity of BiP as a key regulator of proinsulin folding, we may find a promising treatment strategy for intervening early to prevent or reduce damage to insulin-producing cells,” said Kaufman. Additional authors on the study include Alec Duffey and Pamela Itkin-Ansari at Sanford Burnham Prebys and Peter Arvan at the University of Michigan. The work received support from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Cancer Institute, and Breakthrough T1D, formerly known as JDRF.
Frequently Asked Questions
What causes pancreatic beta cells to become overwhelmed in diabetes?
As prediabetes advances toward diabetes, rising blood glucose demands increased insulin production. This surge causes proinsulin precursors to misfold, accumulating inside cells and creating cellular stress that damages beta cells.
What is the role of BiP and p58IPK in insulin production?
Binding immunoglobulin protein (BiP) acts as a core chaperone protein, while p58IPK functions as a cochaperone. Together, according to Sanford Burnham Prebys and University of Michigan researchers, they coordinate the proper folding, transport, and management of proinsulin inside beta cells.
Do current diabetes medications fix protein-folding issues?
No. Most existing medications control blood sugar by helping tissues absorb glucose or forcing the pancreas to release more insulin, rather than correcting the underlying protein-folding defects.
Worth a look